Suggestions
Amrit Ray, M.D.
Corporate Board Director • Physician Researcher & Advocate for Healthcare Access • Former Global President, Head of R&D and Medical, Pfizer
Amrit Ray is a prominent figure in the life sciences sector, currently serving as the Chairman of the Board of Directors at ArisGlobal. His extensive background encompasses leadership roles across various organizations, particularly in healthcare and technology.
Professional Background
- Experience: Amrit Ray has a wealth of experience in the life sciences industry, having held senior positions that leverage his expertise in operational management and strategic development. His leadership has been pivotal in guiding ArisGlobal through significant growth phases.
- Education: He possesses advanced degrees that complement his professional endeavors, allowing him to navigate complex challenges within the life sciences landscape effectively.
Role at ArisGlobal
As Chairman, Ray plays a crucial role in overseeing the strategic direction of ArisGlobal, a company known for its innovative LifeSphere technology platform that supports drug development and regulatory compliance. His contributions are instrumental in shaping the company's vision and ensuring its alignment with industry advancements.
Additional Information
Ray's leadership style is characterized by a focus on innovation and collaboration, which has helped ArisGlobal maintain its competitive edge in the market. His insights and decision-making capabilities are highly regarded within the organization and the broader life sciences community.
For more details about his professional journey, you can view his LinkedIn profile under the username amrit-ray-m-d-329670.
Highlights
What a joy to return to a sunny Connecticut (where I started my own pharma career) to give the keynote speech on “Envisioning the Future of Medicine” to the incredible colleagues at this year's annual convention of Statistics in Pharmaceuticals.
💡Quantifying uncertainty through rigorous statistics is a core capability to enabling strategic decision-making in life sciences, including in understanding patients and disease, clinical trial and RWE study designs and outcomes, regulatory assessments, and access systems. 💡Equally, the art of communicating complex analyses simply, objectively and transparently, is critical to earning society's trust in science.
Thank you to Prof. Ming-Hui Chen and Dr. Chenguang Wang, our great hosts University of Connecticut, Juliet, Sana, Wasiuddin, Lucy, Abhishek and all of the esteemed speakers and attendees. Well done to generous supporters Amgen, BeiGene, Pfizer, Gilead Sciences, Eli Lilly and Company, and Regeneron for your commitment to growing the next wave of talent!
#trust #pharmaceuticals #medicine #clinicaltrials #statistics #decisionmaking
Congrats to Prof. Jennifer E. Miller and Bioethics International for 15 years of leading the Pharmaceutical Executive Roundtable and exemplifying the old proverb — “If you want to go far, go together."
It was an honor to moderate a dialogue with Seema Verma, Thomas Lee, MD, Ipek Özer Stillman, Steve Pascoe, Tanisha Carino and Frank Marra on the complexities of healthcare delivery and Access to Medicines for Patients in the US.
Well done to Lauren Rogge, Yele Aluko MD, MBA, FACC, and EY, and Jeremy Abbate and Scientific American for supporting, and to Elisabeth Armstrong, John Wig, David Leventhal, Darryl Sleep, MD (MBBCh, FCS(SA)), Mike Rea, Greg Licholai, Pierre Theodore and all who joined to support transparency and ethics in pharma.
#transparency #pharma #ethics
